TAK-875

TAK-875

A GPR40 agonist in Phase-III trials, which activates a receptor that stimulates and regulates insulin production, enhancing insulin secretion in response to changes in serum glucose levels. It has little effect on insulin secretion when serum glucose is normal, and may reduce the risk of hypoglycaemia.
References in periodicals archive ?
The oral, highly potent, and selective free fatty acid receptor 1 agonist TAK-875 significantly improved glycemic control in patients with type 2 diabetes without increasing treatment-emergent hypoglycemic events in a phase II, randomized, controlled trial comparing TAK-875, glimepiride, and placebo.
At weeks 4, 8, and 12 of treatment, all of the 303 patients who were randomized to receive treatment with TAK-875 at doses ranging from 6.
25-mg TAK-875 group was smaller than that in the glimepiride group, they noted.
26, 2012 /PRNewswire/ --Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited ("Takeda"), were published online first in The Lancet.
Discovered by Takeda, through orphan G-protein-coupled receptors (GPCRs) research, TAK-875 is the first GPR40 agonist to reach late stage (Phase 3) clinical development, and completed studies have demonstrated glucose-lowering effects in patients with type 2 diabetes by stimulating glucose-dependent insulin secretion.
Because of its observed ability to potently stimulate insulin secretion and improve glycemic control with less or no hypoglycemia, these data further support TAK-875 as a potential therapy for the treatment of type 2 diabetes in the future.
Completed studies of TAK-875, discovered by Takeda, have suggested glucose-lowering effects in patients with type 2 diabetes by enhancing glucose-dependent insulin secretion.
Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals," said Thomas Strack, M.
TAK-875 is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells.
TAK-875 is the first GPR40 agonist to reach clinical development, and completed studies have demonstrated glucose-lowering effects in patients with type 2 diabetes by stimulating glucose-dependent insulin secretion.
These data presented as a late breaker at ADA further evaluate the potential of TAK-875 as a novel therapeutic option for patients living with type 2 diabetes," said Thomas Strack, M.
The data were presented from a Phase 2 randomized, double-blind, placebo- and active (glimepiride) comparator-controlled, parallel-group, multicenter study, which was conducted to evaluate the efficacy, safety and tolerability of once-daily treatment with five different doses of TAK-875 (6.